Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference
27 February 2014 - 1:00AM
Marketwired
Arch Therapeutics to Present at The Wall Street Analyst Forum
Institutional Investor Conference
Company Presentation Will Be Webcast Live on Monday, March 3rd
at 12:05 PM EST
WELLESLEY, MA--(Marketwired - Feb 26, 2014) - Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life sciences
company and developer of the AC5 Surgical Hemostatic Device™, a
novel product aimed at controlling bleeding and fluid loss in order
to provide faster and safer surgical and interventional care, is
pleased to announce that Company CEO, Terrence W. Norchi, MD, is
scheduled to present a corporate overview at The Wall Street
Analyst Forum Conference in Manhattan at The University Club of NYC
on Monday, March 3rd at 12:05 PM EST.
The Arch Therapeutics presentation will be provided via a live
audio and high-definition video webcast and can be accessed at
either of the following links:
http://www.visualwebcaster.com/event.asp?id=98086 or
http://www.analyst-conference.com. The presentation will be
available on the Arch website following the event at
www.archtherapeutics.com.
Arch Therapeutics recommends registering at least 10 minutes
prior to the start of the presentation to ensure timely access. You
will require a Microsoft Silverlight viewer (a free download from
the presentation link) to participate.
About The Wall Street Analyst Forum Conferences
Our March 2014 investor conference is our 24th Annual Investor
Conference. We have been a leading sponsor of institutional
investor conferences in New York City, Boston and London since
1989. Over 2200 corporations, from General Electric, Pfizer,
Mattel to Nokia, have presented. Institutional investors from
2000 money management firms have attended. In 1998 we received
extensive coverage in the financial press for conducting the first
live webcast of individual corporate meetings from an investor
conference.
About Arch Therapeutics, Inc. (OTCQB: ARTH) Arch Therapeutics,
Inc. is a medical device company developing a novel approach to
stop bleeding (hemostasis) and control leaking (sealant) during
surgery and trauma care. Arch is developing products based on an
innovative self-assembling peptide technology platform to make
surgery and interventional care faster and safer for patients.
Arch's flagship development stage product candidate, known as AC5™,
is being designed to achieve hemostasis in minimally invasive and
open surgical procedures. Find out more at
www.archtherapeutics.com.
Notice Regarding Forward-Looking Statements This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and
Section 21(e) of the Securities Exchange Act of 1934, as amended.
Statements in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future.
Such forward-looking statements include, among other things,
references to novel technologies and methods, our business and
product development plans and projections, or market information.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the inherent uncertainties associated with
developing new products or technologies and operating as a
development stage company, our ability to retain important members
of our management team and attract other qualified personnel, our
ability to raise the additional funding we will need to continue to
pursue our business and product development plans, our ability to
develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements
are made as of the date of this news release, and we assume no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements. Although we believe that any
beliefs, plans, expectations and intentions contained in this press
release are reasonable, there can be no assurance that any such
beliefs, plans, expectations or intentions will prove to be
accurate. Investors should consult all of the information set forth
herein and should also refer to the risk factors disclosure
outlined in the reports and other documents we file with the SEC,
available at www.sec.gov.
On Behalf of the Board, Terrence W. Norchi, MD Arch
Therapeutics, Inc.
Contact: ARTH Investor Relations Toll Free: +1-855-340-ARTH
(2784) (US and Canada) Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Dec 2024 to Jan 2025
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Jan 2024 to Jan 2025
